Solitomab
As of the edition of 20 October 2026, Solitomab is an antibody: went quiet in 2015; acts on CD3D, CD3E and CD3G and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2015
- Kind
- Antibody
- Registered trials
- 1, 0 stopped early
- Disease areas
- Chemically induced; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2008 to now |